Ads
related to: fda approved drugs for pulmonary hypertension side effectsdiscoverpanel.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Soluble guanylate cyclase (sGC) stimulators are a class of drugs developed to treat heart failure, pulmonary hypertension, and other diseases. The first-in-class medication was riociguat, approved in 2013 for pulmonary hypertension. [1] [2] They have also been investigated for hypertension, systemic sclerosis, and sickle cell disease. [3] [1]
The U.S. Food and Drug Administration (FDA) granted selexipag orphan drug designation for pulmonary arterial hypertension [12] and for the treatment of chronic thromboembolic pulmonary hypertension. [13] It was approved by the FDA in December 2015. [3] [14] In the European Union, the drug was approved in May 2016. [4] [9]
However, the medical officer of the Food and Drug Administration (FDA), Leo Lutwak, insisted upon a black box warning of pulmonary hypertension risks. After Lutwak refused to approve the drug, the FDA management had James Milton Bilstad, FDA Senior Drug Evaluator, sign it and approve the drug with no black box warning for marketing in 1996. [1]
Sotatercept, sold under the brand name Winrevair is a medication used for the treatment of pulmonary arterial hypertension. [1] It is an activin signaling inhibitor, [1] based on the extracellular domain of the activin type 2 receptor expressed as a recombinant fusion protein with immunoglobulin Fc domain (ACTRIIA-Fc). [4]
Macitentan, sold under the brand name Opsumit, is an endothelin receptor antagonist developed by Actelion and approved for the treatment of pulmonary arterial hypertension (PAH). [5] Macitentan is a dual endothelin receptor antagonist, meaning that it acts as an antagonist of two endothelin (ET) receptor subtypes, ET A and ET B. [5]
Treprostinil, sold under the brand names Remodulin for infusion, Orenitram for oral, and Tyvaso for inhalation, is a vasodilator that is used for the treatment of pulmonary arterial hypertension. [6] Treprostinil was approved for use in the United States in May 2002. [7]
Ads
related to: fda approved drugs for pulmonary hypertension side effectsdiscoverpanel.com has been visited by 10K+ users in the past month